INVESTORS

Investor Relations

Recent News

Investor Alerts

Jun 5, 2017

Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737

May 30, 2017

Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737

May 24, 2017

Sierra Oncology to Present Innovative Clinical Trial Enhancements Leveraging Chk1 Synthetic Lethality in Two Posters at ASCO Annual Meeting

View all news releases

Events and Webcasts

Jefferies Healthcare Conference - New York, NY

Thursday, June 8, 2017

2:00pm EDT

View all events and webcasts

Annual Meeting of Stockholders

Tuesday, June 13, 2017
10:00 am PT
Fairmont Hotel Vancouver, 900 West Georgia Street, Vancouver, BC

Proxy Documents:

Latest Presentation

Beyond PARP - Next Generation DDR Therapeutics, Q2 2017

View All Presentations

Publications

A Phase 1 Study of SRA737 Administered Orally in Patients with Advanced Cancer

VIEW PUBLICATIONS